Sectors
TRVI
Trevi Therapeutics, Inc.
16.42
6 x 13.61
2 x 23.73
bid
ask
-
0.37
2.20%
03:07 PM
timesize
| Ytd | 31.15% | |
| 1y | 126.17% |
16.08
day range
16.73
7.01
52 week range
19.50
| Open | 16.66 | Prev Close | 16.79 | Low | 16.08 | High | 16.73 | Mkt Cap | 2.34B |
| Vol | 956.81K | Avg Vol | 2.13M | EPS | -0.35 | P/E | N/A | Forward P/E | -29.10 |
| Beta | 1.03 | Short Ratio | 6.00 | Inst. Own | 107.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 18.03 | 200-d Avg | 13.90 | 1yr Est | 28.18 |
| Income Statement | |||
| Operating Expenses | 20.51M | ||
| Research and Development Expense | 15.15M | ||
| Selling, General and Administrative Expense | 5.36M | ||
| Operating Income | -20.51M | ||
| Income Tax Expense | -19.00K | ||
| Net Income | -17.80M | ||
| Net Income Common Stock | -17.80M | ||
| Net Income Common Stock (USD) | -17.80M | ||
| Consolidated Income | -17.80M | ||
| Earnings per Basic Share | -0.11 | ||
| Earnings per Basic Share (USD) | -0.11 | ||
| Earnings per Diluted Share | -0.11 | ||
| Earning Before Interest & Taxes (EBIT) | -17.82M | ||
| Earning Before Interest & Taxes (USD) | -17.82M | ||
| Weighted Average Shares | 156.60M | ||
| Weighted Average Shares Diluted | 156.60M | ||
| Balance Sheet | |||
| Cash and Equivalents | 54.30M | ||
| Cash and Equivalents (USD) | 54.30M | ||
| Investments | 264.57M | ||
| Investments Current | 264.57M | ||
| Current Assets | 325.71M | ||
| Property, Plant & Equipment Net | 878.00K | ||
| Total Assets | 330.52M | ||
| Debt Current | 329.00K | ||
| Total Debt | 605.00K | ||
| Current Liabilities | 8.74M | ||
| Debt Non-Current | 276.00K | ||
| Total Liabilities | 9.01M | ||
| Accumulated Retained Earnings (Deficit) | -360.79M | ||
| Accumulated Other Comprehensive Income | -425.00K | ||
| Shareholders Equity | 321.51M | ||
| Shareholders Equity (USD) | 321.51M | ||
| Assets Non-Current | 4.81M | ||
| Total Debt (USD) | 605.00K | ||
| Liabilities Non-Current | 276.00K | ||
| Trade and Non-Trade Payables | 3.10M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 34.00K | ||
| Net Cash Flow from Financing | 164.36M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 34.89M | ||
| Capital Expenditure | -124.00K | ||
| Issuance (Purchase) of Equity Shares | 164.80M | ||
| Net Cash Flow from Investing | -112.04M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -111.91M | ||
| Net Cash Flow from Operations | -17.43M | ||
| Share Based Compensation | 3.27M | ||